MONTREAL, CANADA--(Marketwire - August 04, 2008) - Theratechnologies (TSX: TH) today announced positive data related to body image for patients treated with tesamorelin in both its first and confirmatory Phase 3 clinical trials, in two poster presentations at the XVII International AIDS Conference in Mexico City, Mexico. Body image parameters are considered an important secondary endpoint and a clinical benefit of both Phase 3 studies. The Company will also sponsor a symposium entitled “Body Fat Changes and Metabolic Complications in the General Population and in HIV” at the Conference.
